Silence Therapeutics plc (NASDAQ: SLN) reported Q1 EPS of ($0.11), $0.03 better than the analyst estimate of ($0.14). Revenue for the quarter came in at $400 thousand versus the consensus estimate of $1.32 million.

For earnings history and earnings-related data on Silence Therapeutics plc (SLN) click here.